Success for First-Line PARP Inhibition in Ovarian Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-121
Abstract: The use of PARP inhibitors as first-line maintenance therapy for advanced ovarian cancer improves progression-free survival, according to three phase III studies. The data also suggest that patients other than those with BRCA1/2 mutations may… read more here.
Keywords: ovarian cancer; cancer; line parp; first line ... See more keywords